Robin Ellis #
Robin’s experience brings a commercial perspective to the assessment of global IP strategies in the pharmaceutical; medical device and chemical sectors.
Robin joined Reddie & Grose in 2019 and is the firm’s first partner to be based permanently in our Munich office. Robin, a British/German national, started his career in 2001 with Reddie & Grose in London before deciding in 2006 to move to Germany to work in-house for one of the world’s leading pharmaceutical companies. In his final role in-house Robin was the global head of the small molecules patent team.
Since returning to private practice, Robin’s work reflects his in-house experiences and focuses on commercial and contentious matters including oppositions; freedom to operate assessments; licencing and launch & litigation strategies in European and non-European jurisdictions. In his 20+ years in the profession Robin has supported numerous product launches that required navigating complex patent landscapes.
Robin also advises his pharmaceutical and biotech clients on the interplay between regulatory and patent derived exclusivities and helps devise strategies relating to supplementary protection certificates and patent term extensions.
Complimenting his chemistry and pharmaceutical background, Robin has a wealth of experience working with medical devices, supporting clients in technologies ranging from inhalers to cranial perforators.
Robin enjoys snowboarding, cricket and rugby (although his playing days are long behind him) and faces a daily battle trying to convince his two young children to support the slightly less fashionable Norwich City over Bayern Munich.
Publications in the media:
- How smaller medtech companies can protect their IP – Medical Technology
- Patenting medical devices: navigating a minefield – Industrial News
- How can smaller medtech companies protect their IP?
- Different strokes
- Patenting Medical Devices: Navigating a Minefield
- On the horizon
- Counterfeit medical devices: On the rise during COVID-19?